Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Ambu A-S expects increase in revenue and profit in latest quarter

Ambu A-S will release its quarterly results on 5 November 2026. Two analysts on average expect earnings per share of 0.862 DKK, up from 0.430 DKK in the year-ago quarter. Six analysts forecast revenue to rise 13.54 percent to around 1.66 billion DKK. For the past fiscal year, the analyst consensus is 2.40 DKK earnings per share and revenue of 6.44 billion DKK. » More on finanzen.net
Ambu share falls 15% after slightly missed quarter

Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » More on de.investing.com
Ambu forecasts significant quarterly growth in EPS and revenue

Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » More on finanzen.net
Ambu confirms outlook after Q1 – endoscopy growth offsets currency and tariff headwinds

Ambu reported organic revenue growth of 8.6% in Q1 2025/26 (reported 3.2% after currency impact) and total revenue of DKK 1,558m. The driver was the Endoscopy Solutions segment with 14.4% organic growth; Anesthesia & Patient Monitoring was flat. EBIT margin before special items fell to 10.5%; adjusted for tariffs and currency effects it would be 15.2%. Free cash flow was DKK 13m. Ambu confirmed its full-year outlook of 10–13% organic revenue growth and a target EBIT margin of 12–14%, but continued to see currency and tariff risks. » More on de.investing.com
Ambu records strong organic growth in Q2 2026 despite currency headwinds

Ambu reports organic revenue growth of 8.0% year-to-date and 7.3% in the second quarter, with the endoscopy solutions segment accounting for 63% of revenue. Reported growth in Q2 was dampened to 1.2% by adverse exchange rates. Reported EBIT margin was 11.0%, adjusted to 14.5%, and free cash flow amounted to DKK 104 million. The company maintains its guidance, sees opportunities in the shift to single-use endoscopes, and cites exchange rates, tariffs and supply-chain inflation as key risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Ambu has already paid €0.0549 in dividends. The last payout was in December 2025.

Financials

In the last quarter, Ambu had revenue of €227.41m and net profit of €33.04m

(EUR)	September 2026	YoY
Revenue	227.41m	16.03%
Gross profit	136.44m	16.09%
Net profit	33.04m	114.87%
EBITDA	53.37m	60.95%

Fundamentals

Metric	Value
Market capitalization	€2.65bn
Number of shares	232.24m
52-week high/low	€12.54 - €8.53
Dividend yield	0.47%
Dividends TTM	€0.0549
Beta	1.34
P/E ratio	36.01
PEG ratio	5.86
P/B ratio	3.66
P/S ratio	3.13

Company profile

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, head immobilizers, CPR breathing barriers, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Name	Ambu
CEO	Britt Meelby Jensen
Headquarters	Ballerup, cr Denmark
Website	ambu.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	11/02/2004
Employees	5,384